


WO 01/17959

PCT/US00/24514


What is claimed is:

1. A compound according to formula (I):




(I)

wherein:













 R^1 is Het- or Ar; R^2 is

or



or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in which R^1 is:




or

WO 01/17959


PCT/US00/24514

in which R' is C₁₋₄alkyl and R'' is phenyl, benzyl or -CH₂CF₃; or R' and R'' are joined to form a morpholinyl ring.

3. A compound according to claim 1 in which R² is:



4. A compound according to claim 1 in which R² is:



5. A compound which is:

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-(trifluoromethyl)phenyl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[(N-methyl-N-phenylamino)carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[(morpholin-4-yl)carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[[N-methyl-N-(2,2,2-trifluoroethyl)amino]carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-(trifluoromethyl)thiazol-2-yl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-(3-methylthiazol-2-yl)butanoic acid;

(S)-3-(3-fluorophenyl)-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid;

(±)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(pyridin-3-yl)butanoic acid;

(S)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(pyridin-3-yl)butanoic acid; or

(S)-3-(pyridin-3-yl)-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid;

or a pharmaceutically acceptable salt thereof.

- 5 *sub*
of
6. A pharmaceutical composition which comprises a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition which comprises a compound according to claim 1, an antineoplastic agent and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition according to claim 6 wherein the
10 antineoplastic agent is topotecan or cisplatin.
9. A pharmaceutical composition which comprises a compound according to claim 1, an inhibitor of bone resorption and a pharmaceutically acceptable carrier.
- 15 10. A method of treating a disease state in which antagonism of the $\alpha_v\beta_3$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.
- 20 11. A method of treating a disease state in which antagonism of the $\alpha_v\beta_5$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.
- 25 12. A method of treating osteoporosis which comprises administering to a subject in need thereof a compound according to claim 1.
- 30 13. A method for inhibiting angiogenesis, tumor growth or tumor metastasis which comprises administering to a subject in need thereof a compound according to claim 1.
- 35 14. A method of treating atherosclerosis, restenosis or rheumatoid arthritis which comprises administering to a subject in need thereof a compound according to claim 1.
15. A method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound according to claim 1 and an antineoplastic agent.

WO 01/17959

PCT/US00/24514

16. The method according to claim 15 wherein the antineoplastic agent is topotecan or cisplatin.
17. A method of treating osteoporosis or inhibiting bone loss which comprises administering stepwise or in physical combination a compound according to claim 1 and an inhibitor of bone resorption.
18. A compound according to any one of claims 1 to 5 for use as a medicament.
19. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of diseases in which antagonism of the $\alpha_v\beta_3$ receptor is indicated.
20. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of diseases in which antagonism of the $\alpha_v\beta_5$ receptor is indicated.
21. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of osteoporosis.
22. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the inhibition of angiogenesis, tumor growth or tumor metastasis.
23. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of atherosclerosis, restenosis or rheumatoid arthritis.
24. The use of a compound of the formula (I) as defined in claim 1 and an antineoplastic agent in the manufacture of a medicament for the inhibition of tumor growth in physical combination or for stepwise administration.
25. The use according to claim 24 wherein the antineoplastic agent is topotecan or cisplatin.

WO 01/17959

PCT/US00/24514

26. The use of a compound of the formula (I) as defined in claim 1 and an inhibitor of bone resorption in the manufacture of a medicament for the treatment of osteoporosis in physical combination or for stepwise administration.